The company was founded by Christian Ottmann, Lucas Brunsveld, and Michelle Arkin and specializes in small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins. Their drugs selectively augment the endogenous tumor suppression activity of 14-3-3 proteins bound to transcription factors and oncoproteins that have proven challenging to modulate with conventional approaches. AmbAgon's platform approach will allow physicians to address major unmet clinical needs beyond oncology.